Scarica l'app Stockscreener
13.89
16.53%
1.97
Dopo l'orario di chiusura:
14.04
0.15
+1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.92
Aprire:
$12.12
Volume 24 ore:
2.16M
Relative Volume:
1.77
Capitalizzazione di mercato:
$448.55M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-16.73
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+41.45%
1M Prestazione:
+8.01%
6M Prestazione:
-31.03%
1 anno Prestazione:
+181.17%
Intervallo 1D:
$12.02
$14.08
Intervallo di 1 settimana:
$9.43
$14.08
Portata 52W:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
13.89 | 448.55M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges and Strategic Advancements - GuruFocus
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - simplywall.st
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? - Yahoo Finance
(CAPR) Trading Advice - news.stocktradersdaily.com
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day - The Manila Times
Promising DMD Treatment Update: Capricor CEO Reveals Latest Development Progress - Stock Titan
Capricor Therapeutics Plunges 19.91% Amid Clinical Trials Focus - AInvest
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - simplywall.st
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
(CAPR) Trading Signals - Stock Traders Daily
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - Benzinga
Cantor Fitzgerald maintains $30 target on Capricor stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $30 target on Capricor stock - Investing.com
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts - Benzinga
Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy - The Globe and Mail
Capricor Therapeutics Reports 2024 Financial Results - TipRanks
Capricor: Q4 Earnings Snapshot - mySA
Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com Canada
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases - MarketScreener
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com Canada
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Capricor's DMD Breakthrough: FDA Fast-Tracks Novel Therapy as Cash Position Hits $151.5M - StockTitan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - simplywall.st
While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance
Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance
H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK
Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire
Capricor reports promising DMD treatment results - Investing.com
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com
Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia
Capricor Therapeutics Reports 52% Slowing of Duchenne Muscular Dystrophy Disease Progression with Deramiocel in 3-Year Study Presentation at MDA Conference - Nasdaq
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capricor Therapeutics Inc Azioni (CAPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):